Yurpeak (Zenagamtide)
The Next Generation GLP-1/GIP Dual Agonist
Yurpeak (chemical name Zenagamtide) is a potent new dual GLP-1 and GIP receptor agonist entering the global market in 2026. Developed as a high-efficacy alternative to existing dual agonists, it shows promising results in both weight loss and glycemic control.
Mechanism of Action: How Yurpeak Works
Yurpeak operates by activating two key incretin receptors: Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP). This dual-action approach mimics the effectiveness of Tirzepatide but uses a unique molecular scaffold designed for higher stability and potentially lower side-effect profile.
By targeting both receptors, Yurpeak enhances insulin secretion, suppresses glucagon, and significantly slows gastric emptying, leading to rapid satiety and sustained weight loss.
Clinical Trial Highlights (Phase III)
Yurpeak vs. Mounjaro (Tirzepatide)
While both are dual agonists, early comparative data suggest that Yurpeak may have a more "peaked" satiety effect, making it particularly effective for those who experience "breakthrough hunger" on Tirzepatide. However, the dosing schedule for Yurpeak is typically more frequent in the initiation phase to minimize GI distress.
Yurpeak is currently seeing massive adoption in the Asian and European markets, with FDA submission pending in the United States for late 2026.
Initiating Your Yurpeak Protocol
Guide FAQs
As of mid-2026, Yurpeak is available through specific research channels and is in the final stages of regulatory approval in several territories.
The side-effect profile is similar to other GLP-1s: nausea, mild diarrhea, and fatigue, typically concentrated in the first 48 hours after injection.
Most clinical participants achieve optimal results at the 1.5mg to 2.0mg weekly dose.
Track Your Yurpeak Progress in Shotlee
Shotlee is the first app to support custom tracking for the Yurpeak (Zenagamtide) protocol.